Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics

Schizophrenia Research

Volumn 32, Issue 2, 1998, Pages 107-113

  Ohmori, Osamu ^a   Suzuki, Takashi ^a   Kojima, Hideki ^a   Shinkai, Takahiro ^a   Terao, Takeshi ^a   Mita, Takashi ^b   Abe, Kazuhiko ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KYUSHU WOMEN'S UNIVERSITY   (Japan)

Author keywords

CYP2D6*10 allele; Debrisoquine 4 hydroxylase; Genetic polymorphism; Schizophrenia; Tardive dyskinesia

Indexed keywords

DEBRISOQUINE; OXYGENASE;

ADULT; AGED; ALLELE; ARTICLE; DNA POLYMORPHISM; FEMALE; GENE AMPLIFICATION; GENOTYPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHIZOPHRENIA; STATISTICAL ANALYSIS; TARDIVE DYSKINESIA;

ALLELES; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DYSKINESIA, DRUG-INDUCED; FEMALE; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 0032572599     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00018-8     Document Type: Article

References (41)

1. Alván, G., Bechtel, P., Iselius, L., Gundert-Remy, U., 1990. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39, 533-537.
2. Andreassen, O.A., MacEwan, T., Gulbrandsen, A.K., McCreadie, R.G., Steen, V.M., 1997. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology 131, 174-179.
3. Armstrong, M., Daly, A.K., Cholerton, S., Bateman, D.N., Idle, J.R., 1992. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 339, 1017-1018.
4. Armstrong, M., Fairbrother, K., Idle, J.R., Daly, A.K., 1994. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 4, 73-81.
5. Armstrong, M., Daly, A.K., Blennerhassett, R., Ferrier, N., Idle, J.R., 1997. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br. J. Psychiatry 170, 23-26.
6. Brøsen, K., Sindrup, S.H., Skjelbo, E., Nielsen, K.K., Gram, L.F., 1993. Role of genetic polymorphism in psychopharmacology: an update. Psychopharmacol. Ser. 10, 199-211.
7. Casey, D.E., 1991. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr. Res. 4, 109-120.
8. Dahl, M.L., Yue, Q.Y., Roh, H.K., Johansson, I., Säwe, J., Sjöqvist, F., Bertilsson, L., 1995. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 5, 159-164.
9. Dahl-Puustinen, M.L., Lidén, A., Alm, C., Nordin, C., Bertilsson, L., 1989. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin. Pharmacol. Ther. 46, 78-81.
10. Daly, A.K., Brockmöller, J., Broly, F., Eichelbaum, M., Evans, W.E., Gonzalez, F.J., Huang, J.D., Idle, J.R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer, U.A., Nebert, D.W., Steen, V.M., Wolf, C.R., Zanger, U.M., 1996. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6, 193-201.
11. Faurbye, A., Rasch, P.J., Petersen, P.B., Brandborg, G., Pakkenberg, H., 1964. Neurological symptoms in pharmacotherapy of psychoses. Acta. Psychiatr. Scand. 40, 10-27.
12. Fronne-Pfister, R., Bargetzi, M.J., Meyer, U.A., 1987. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (p450bufl, p450dbl) catalyzing debrisoquine 4-hydroxylation. Biochem. Biophys. Res. Commun. 148, 1144-1150.
13. Glazer, W.M., Morgensterrn, H., Niedzwiecki, D., Hughes, J., 1988. Heterogeneity of tardive dyskinesia: a multivariate analysis. Br. J. Psychiatry 152, 253-259.
14. Guy, W. (Ed.), 1976. ECDEU Assessment Manual for Psychopharmacology. Publication ADM 534-537. US Department of Health, Education and Welfare, Washington, DC.
15. Heim, M., Meyer, U.A., 1990. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 336, 529-532.
16. Horai, Y., Nakano, M., Ishizaki, T., Ishikawa, K., Zhou, H.H., Zhou, B.J., Liao, C.L., Zhang, L.M., 1989. Metoprolol and mephenytoin oxidation polymorphisms in far eastern oriental subjects: Japanese versus mainland Chinese. Clin. Pharmacol. Ther. 46, 198-207.
17. Inada, T., Yagi, G., 1995. Current topics in tardive dyskinesia in Japan. Jpn. J. Clin. Psychiatry 49, 239-244.
18. Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M.L., Sjöqvist, F., Ingelman-Sundberg, M., 1993. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 90, 11825-11829.
19. Johansson, I., Oscarson, M., Yue, Q.Y., Bertilsson, L., Sjöqvist, F., Ingelman-Sundberg, M., 1994. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46, 452-459.
20. Jurima-Romet, M., Foster, B.C., Casley, W.L., Rode, A., Vloshinsky, P., Huang, H.S., Geertsen, S., 1997. CYP2D6-related oxidation polymorphism in a Canadian Inuit population. Can. J. Physiol. Pharmacol. 75, 165-172.
21. Koshino, Y., Madokoro, S., Ito, T., Horie, T., Mukai, M., Isaki, K., 1992. A survey of tardive dyskinesia in psychiatric inpatients in Japan. Clin. Neuropharmacol. 15, 34-43.
22. Kroemer, H.K., Eichelbaum, M., 1995. 'It's the gene, stupid' Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci. 56, 2285-2298.
23. Lai, M.L., Wang, S.L., Lai, M.D., Lin, E.T., Tse, M., Huang, J.D., 1995. Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther. 58, 264-268.
24. Lee, E.J.D., Jeyaseelan, K., 1994. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br. J. Clin. Pharmacol. 37, 605-607.
25. Llerena, A., Alm, C., Dahl, M.L., Ekqvist, B., Bertilsson, L., 1992. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther. Drug Monit. 14, 92-97.
26. Miller, C.H., Simioni, I., Oberbauer, H., Schwitzer, J., Barnas, C., Kulhanek, F., Boissel, K.E., Meise, U., Hinterhuber, H., Fleischhacker, W.W., 1995. Tardive dyskinesia prevalence rates during a ten-year follow-up. J. Nerv. Ment. Dis. 183, 404-407.
27. Nakamura, K., Goto, F., Ray, W.A., McAllister, C.B., Jacqz, E., Wilkinson, G.R., Branch, R.A., 1985. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Pharmacol. Ther. 38, 402-408.
28. 3H]GBR-12935 binding proteins. Arch. Biochem. Biophys. 276, 424-432.
29. Pourcher, E., Baruch, P., Bouchard, R.H., Filteau, M.J., Bergeron, D., 1995. Neuroleptic associated tardive dyskinesias in young people with psychoses. Br. J. Psychiatry 166, 768-772.
30. Schooler, N.R., Kane, J.M., 1982. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 39, 486-487.
31. Smith, C.A.D., Gough, A.C., Leigh, P.N., Summers, B.A., Harding, A.E., Maranganore, D.M., Sturman, S.G., Schapira, A.H.V., Williams, A.C., Spurr, N.K., Wolf, C.R., 1992. Debrisoquine hydroxylase gene polymorphisms and susceptibility to Parkinson's disease. Lancet 339, 1375-1377.
32. Spina, E., Ancione, M., Di Rosa, A.E., Meduri, M., Caputi, A.P., 1992. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur. J. Clin. Pharmacol. 42, 347-348.
33. Steiner, E., Bertilsson, L., Säwe, J., Bertling, I., Sjöqvist, F., 1988. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin. Pharmacol. Ther. 44, 431-435.
34. Sweet, R.A., Mulsant, B.H., Gupta, B., Rifai, A.H., Pasternak, R.E., McEachran, A., Zubenko, G.S., 1995. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch. Gen. Psychiatry 52, 478-486.
35. Tseng, C.Y., Wang, S.L., Lai, M.D., Lai, M.L., Huang, J.D., 1996. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther. 60, 177-182.
36. Tyndale, R., Aoyama, T., Broly, F., Matsunaga, T., Inaba, T., Kalow, W., Gelboin, H.V., Meyer, U.A., Gonzalez, F.J., 1991. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1, 26-32.
37. Wang, S.L., Huang, J.D., Lai, M.D., Liu, B.H., Lai, M.L., 1993. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin. Pharmacol. Ther. 53, 410-418.
38. Wang, S.L., Lai, M.D., Lai, M.L., Huang, J.D., 1995. R296C and other CYP2D6 mutations in Chinese. Pharmacogenetics 5, 385-388.
39. Woolf, B., 1955. On estimating the relationship between blood group and disease. Ann. Hum. Genet. 19, 251-253.
40. Yokota, H., Tamura, S., Furuya, H., Kimura, S., Watanabe, M., Kanazawa, I., Kondo, I., Gonzalez, F.J., 1993. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 3, 256-263.
41. von Bahr, C., Moving, G., Nordin, C., Lidén, A., Hammarlund-Udenaes, M., Hedberg, A., Ring, H., Sjöqvisk, F., 1991. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin. Pharmacol. Ther. 49, 234-240.